Overview

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.

Phase:

PHASE2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

bimagrumab
Tirzepatide